Second STOP After Pioglitazone Priming in CML Patients

Summary

Single-center study, prospective, phase II trial. The study objectives are : * To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation. * To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain \< MR4.5 with the combination PIO and TKI administered for at least 6 months.

Timeline

Start

2016-12

Primary completion

2027-12

Completion

2028-12

Drugs

Indications